Therefore in this study, we chose to design FJX1-specific HLA-A2-restricted peptides and MHC class II HLA-DR restricted long peptides and these was then evaluated as potential cancer vaccine targets in FJX1 overexpressing NPCs. The gene discussed is FJX1; the disease is cancer.